U.S., July 14 -- ClinicalTrials.gov registry received information related to the study (NCT07698561) titled 'Linzagolix in Adenomyosis and Recurrent Implantation Failure' on July 06.
Brief Summary: Adenomyosis is associated with impaired endometrial receptivity and reduced implantation rates in assisted reproduction, even when using high-quality embryos. Linzagolix (Yselty, 200 mg) is an oral GnRH receptor antagonist approved for uterine fibroids with a favourable tolerability profile and rapid elimination half-life (18-20 hours) compared to GnRH agonists.
This prospective case series evaluates the efficacy of linzagolix 200 mg administered for 3 to 6 months prior to embryo transfer in patients with confirmed adenomyosis and recurrent imp...